Table 2. . Age and health stage distribution at index among matched eteplirsen-treated and control patients.
| Eteplirsen-treated (n = 389) | Control (n = 389) | p-value | |
|---|---|---|---|
| Age at index in years, mean (SD) | 13.31 (6.31) | 13.31 (6.31) | – |
| Health stage at index, n (%) | |||
| Early ambulatory | 81 (20.1) | 81 (20.1) | – |
| Late ambulatory | 66 (17.0) | 66 (17.0) | – |
| Early non-ambulatory | 169 (43.4) | 169 (43.4) | – |
| Late non-ambulatory | 73 (18.8) | 73 (18.8) | – |
| Exposure to steroid treatment, n (%) | |||
| Pre-index period | 122 (31.4) | 127 (32.6) | 0.70 |
| Follow-up | 135 (34.7) | 159 (40.8) | 0.08 |
| Length of pre-index period in months, mean (SD) | 10.57 (1.76) | 10.63 (1.67) | – |
| Length of follow-up period in months, mean (SD) | 36.62 (15.84) | 48.76 (26.85) | – |
| Length of treatment, mean (SD) | 28.53 (20.10) | – | – |
SD: Standard deviation.